Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
FAIL · Does not pass the screen
28.07 USD
Price as of 28 Oct 2026Daily close, not a live quote
Screened 2026-10-28 · the tape above runs as of 07:18 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price28.07 USD at the 28 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.41)
Last reviewed28 Oct 2026 (1 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 28.07 against the desk's fair-value range, base estimate 42.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.41, read 2026-10-28
Ethical does not pass the values gate
Price28.07 USD
Fair value42.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-21Read Markdown32.63-14.0% to today ✓Markup gives way to Markdown after a 40% rise in 4 weeks
2026-08-21Read Markup23.35+20.2% to today ✓Markdown gives way to Markup after a 60% rise in 7 weeks
2026-07-02Read Markdown14.59+92.4% to today First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Amylyx Pharmaceuticals, Inc. holds its Markdown at $28.07. The statistical read favours the sellers, held for 24 days.
As held on the ledger · 2026-10-28
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 24 days
Price at the screen
$28.07
Valuation
N/A trailing · -26.20 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-0.09
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.79%
Below 33%
Interest-bearing debt is just 1.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
27.15%
Below 33%
Cash held in interest-bearing accounts and securities is 27.2% of assets, under the one-third limit.
Pass
Receivables
68.16%
Below 49%
Money owed to the company is 68.2% of assets, above the 49% limit.
Fail
Revenue purity
15.81%
Below 5%
15.8% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Amylyx Pharmaceuticals,'s business is fine, but its receivables are about 68% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AMLX's ethical verdict changes
Today AMLX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 49.6% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +50% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Early Biotech With No Numbers To Judge
Picture a lab racing to treat cruel brain diseases with one experimental drug and nothing else on the shelf. Amylyx shows zero profit margin, a negative 63 percent return on equity and a forward multiple that sits at minus 14 times because earnings remain absent. The opportunity rating sits at none and the ethical screen flags insufficient data, so we pass without hesitation.
The shares trade at 17.75 dollars against an internal fair value of 21.50, yet that gap means little when the business is still clinical stage and carries an unknown moat. Ten analysts offer a median target near 22 dollars, but the absence of any usable financial ratios leaves the usual checks impossible to run.
Risk sits in the complete lack of earnings visibility and the ethical data hole that blocks any further review. Without those basics the story stays untestable, regardless of disease area or future hopes. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AMLX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-26Markdown$28.57+3.3%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 42% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-10-19Markdown$27.65-1.7%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-10-12Markdown$28.14-13.1%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 13.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-10-02Markdown$32.39-0.7%Entry 8
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-09-21Markdown · changed$32.63+39.7%Entry 7
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 39.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23. Since the last review it its composite score rose.
2026-08-21Markup · changed$23.35+31.5%Entry 6
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 31.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-07-21Markdown$17.75+21.7%Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 21.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-07-18Markdown$14.59+0.0%Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-07-17Markdown$14.59+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-07-03Markdown$14.59+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
